BioMarin Pharmaceutical Inc.BMRNNASDAQ
LOADING
|||
Switch Symbol:
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +28.28% | +15.65% | +14.84% | +15.92% | +4.08% |
| Gross Profit Growth | +22.94% | +19.67% | +13.36% | +16.12% | +14.13% |
| EBITDA Growth | +119.89% | +278.19% | +92.77% | +96.77% | -103.36% |
| Operating Income Growth | +273.11% | +1035.15% | +153.10% | +129.87% | -141.00% |
| Net Income Growth | +162.72% | +513.22% | +109.43% | +124.43% | -128.98% |
| EPS Growth | +171.43% | +500.00% | +106.38% | +123.21% | -128.07% |
| EPS Diluted Growth | +161.90% | +481.82% | +106.52% | +123.64% | -129.09% |
| Weighted Average Shares Growth | +1.17% | +1.17% | +1.11% | +0.70% | +0.84% |
| Weighted Average Shares Diluted Growth | +3.12% | +2.47% | -1.40% | -1.93% | -2.59% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +63.28% | +575.42% | +271.28% | +56.00% | +66.46% |
| Free Cash Flow Growth | +78.48% | +0.00% | +1125.04% | +73.51% | +69.86% |
| Receivables Growth | +35.82% | +4.23% | +16.01% | +23.82% | +1.64% |
| Inventory Growth | +14.26% | +11.33% | +12.03% | +13.23% | +17.20% |
| Asset Growth | +1.38% | +2.15% | +3.99% | +5.51% | +11.15% |
| Book Value per Share Growth | +9.26% | +12.94% | +12.93% | +13.22% | +10.95% |
| Debt Growth | -44.98% | -45.00% | -45.10% | -45.09% | +0.26% |
| R&D Expense Growth | -3.35% | -15.87% | -22.57% | -12.23% | +121.46% |
| SG&A Expenses Growth | +46.87% | -3.05% | -8.76% | -11.67% | +5.88% |